Drugs News and Research

RSS

Galera Therapeutics completes Series 1 financing

Galera Therapeutics, a drug development company focused on novel therapeutics to protect against the side effects and increase the effectiveness of cancer treatment, today announced it has completed a Series 1 financing led by BioGenerator. Also participating in the round is Galera Angels, LLC, an angel investment group, and Analytical Bio-Chemistry Laboratories, Inc., of Columbia Missouri.

16 Jun 2010

Employer health costs slowing, but still face 9 percent increase in 2011

PriceWaterhouseCoopers is estimating that employer health costs will rise 9 percent in 2011, slightly less than they rose in 2010, Reuters reports. "The PriceWaterhouseCoopers team questioned 700 companies in 30 industries for the report. About 60 percent of Americans under the age of 65 get health insurance through an employer. Health benefits are often a major part of any employee compensation package. Most employers, 63 percent, offer a [managed-care] preferred provider organization or PPO, the survey found. And many have raised the deductible, with 43 percent having a deductible of $400 or more, compared to 25 percent in 2009."

16 Jun 2010

Kendle offers BNA imaging technology for monitoring brain electro-physiological network activity

Kendle, a leading, global full-service clinical research organization, today announced it now offers Brain Network Activation imaging providing a non-invasive platform for mapping, monitoring and understanding brain electro-physiological network activity in response to cognitive or physiological stimuli. The BNA imaging technology was developed by ElMindA, a medical technology development company based in Herzliya, Israel.

15 Jun 2010

CDI, Promega enter collaboration for toxicity testing in drug discovery process

Cellular Dynamics International (CDI) and Promega have entered into a research collaboration with the goal of bringing more relevant and highly predictive toxicity testing to the drug discovery process. Pharmaceutical discovery scientists will now be able to combine bioassays with human cardiomyocytes to improve prediction of unintentional, detrimental side effects that have previously remained undetected until late in the development process or after release of the drug to the general public.

15 Jun 2010

AMRI announces acquisition of Hyaluron

AMRI today announced the acquisition of Hyaluron Inc., expanding AMRI's contract manufacturing capabilities to include cGMP manufacturing and sterile filling of parenteral drugs to the biopharmaceutical industry. AMRI has acquired all facilities and equipment as well as a highly trained and experienced staff of professionals with expertise in sterile GMP manufacturing. Purchase price, including debt, was approximately $27 million.

15 Jun 2010

AIDS activists to protest BMS' Reyataz pricing, policies at Goldman Sachs Global Healthcare Conference

“All of AHF's efforts, including this protest, are designed to let people know that BMS is causing great harm to people with HIV/AIDS with its unwarranted pricing of Reyataz”

15 Jun 2010

EMA COMP grants orphan medicinal product designation for Raptor's DR Cysteamine for cystinosis

Raptor Pharmaceutical Corp., announced that the European Medicines Agency's ("EMA") Committee for Orphan Medicinal Products ("COMP") has issued a positive opinion recommending orphan medicinal product designation for DR Cysteamine for the potential treatment of cystinosis.

15 Jun 2010

Orasi Medical signs agreement to study effect of Lundbeck CNS compounds on human brain

Orasi Medical today announced that it has entered an agreement with H. Lundbeck A/S to study the effect of Lundbeck central nervous system compounds on the human brain.

15 Jun 2010

Researchers study how APOE4 becomes a potent risk factor for Alzheimer's disease

A molecule implicated in Alzheimer's disease interferes with brain cells by making them unable to "recycle" the surface receptors that respond to incoming signals, researchers at UT Southwestern Medical Center have found.

15 Jun 2010

ACRO unveils survey findings on decline in physician participation in clinical research

Today, the Association of Clinical Research Organizations (ACRO) unveiled findings from a groundbreaking survey exploring the decline in physician participation in clinical research across the United States and Western European markets at the 46th Drug Information Association (DIA) annual meeting. Over the past decade, the number of physicians participating in clinical research has continued to decrease in the U.S. and countries in Western Europe while participation increased at double digit rates in Asia, Latin America and Central/Eastern Europe.

15 Jun 2010

Comprehensive source for treatment information of atrial fibrillation in the European market

Arlington Medical Resources, a provider of premier market intelligence for the pharmaceutical and diagnostic imaging industries, finds that electrical cardioversion usage patterns in Europe differed dramatically by country in the fourth quarter of 2009. While ECV represented almost half of all cardioversion attempts in Germany, in Spain ECV accounted for only 13% of cardioversion attempts.

15 Jun 2010

Help Conquer Cancer Project taps World Community Grid to discover structure of cancer-related proteins

Scientists have devised a way to automate and accelerate a manual, complex process that enables researchers to more easily discover the structure of cancer-related proteins, and, eventually, formulate cancer cures. This new, automated approach may also help the exploration of other diseases and food-related research.

15 Jun 2010

NOAA, FDA take additional steps to prevent tainted seafood from reaching U.S. market

The National Oceanic and Atmospheric Administration and the U.S. Food and Drug Administration are taking additional steps to enhance inspection measures designed to ensure that seafood from the Gulf of Mexico reaching America's tables is safe to eat.

15 Jun 2010

China Pharmaceuticals first-quarter total revenue rises 50% to $7.05M

China Pharmaceuticals, Inc., one of China's leading manufacturers and distributors of prescription and over-the-counter pharmaceuticals, today announced record sales for its first quarter ended March 31, 2010. The Company's quarterly report on Form 10-Q was filed on May 17, 2010 with the United States Securities and Exchange Commission.

15 Jun 2010

Sulindac shuts down cancer cell growth, initiates cell death: Study

Without knowing exactly why, scientists have long observed that people who regularly take non-steroidal anti-inflammatory drugs like aspirin have lower incidences of certain types of cancer. Now, in a study appearing in Cancer Cell on June 15, investigators at Sanford-Burnham Medical Research Institute and their colleagues have figured out how one NSAID, called Sulindac, inhibits tumor growth.

15 Jun 2010

Pediatric oncologist describes current state of science in combating neuroblastoma

Pediatric oncologist John M. Maris, M.D., describes the current state of the science in combating neuroblastoma, the most common solid cancer of early childhood. In his article in the June 10, 2010 New England Journal of Medicine, "Recent Advances in Neuroblastoma," Maris reviews the field's latest research knowledge—much of it based on efforts by Maris and his colleagues at The Children's Hospital of Philadelphia.

15 Jun 2010

Celator presents new data on CPX-351 liposome injection at European Hematology Association congress

Celator Pharmaceuticals today announced that new data from a preclinical leukemia study in mice demonstrate that its lead product, CPX-351 (Cytarabine:Daunorubicin) Liposome Injection, alone or in combination with clofarabine or azacytidine can improve treatment outcomes compared to the combination of either agent with the conventional (unencapsulated) cytarabine:daunorubicin regimen.

15 Jun 2010

FDA grants Fast Track status for Genzyme's alemtuzumab development program for MS

Genzyme Corporation announced today that its alemtuzumab for multiple sclerosis development program has been granted Fast Track status by the U.S. Food and Drug Administration (FDA). This designation covers patients with relapsing-remitting forms of the disease.

15 Jun 2010

Behind the Numbers report: Employers' medical costs to increase by 9% in 2011

The nation's employers can expect medical costs to increase by 9 percent in 2011, a decrease of 0.5 percent from the 2010 growth rate, according to the annual Behind the Numbers report published today by the PricewaterhouseCoopers LLP Health Research Institute. For the first time, the majority of the American workforce is expected to have a health insurance deductible of $400 or more, as more employers return to "indemnity style" cost-sharing by raising out-of-pocket limits, replacing co-pays with co-insurance and adding high-deductible health plans.

15 Jun 2010

New path involving "innocent spectators" to defeat systemic sclerosis

There is a new path to defeat systemic sclerosis, also called scleroderma because of the hardening of the skin of the patients (from Greek skleros, "hard", and derma, "skin"). This path involves the B-cell of the immune system, so far only considered "innocent spectators," as Catholic University rheumatologist Gianfranco Ferraccioli, among the authors of the important research, puts it.

14 Jun 2010

Drugs News and Research

Galera Therapeutics completes Series 1 financing

Employer health costs slowing, but still face 9 percent increase in 2011

Kendle offers BNA imaging technology for monitoring brain electro-physiological network activity

CDI, Promega enter collaboration for toxicity testing in drug discovery process

AMRI announces acquisition of Hyaluron

AIDS activists to protest BMS' Reyataz pricing, policies at Goldman Sachs Global Healthcare Conference

EMA COMP grants orphan medicinal product designation for Raptor's DR Cysteamine for cystinosis

Orasi Medical signs agreement to study effect of Lundbeck CNS compounds on human brain

Researchers study how APOE4 becomes a potent risk factor for Alzheimer's disease

ACRO unveils survey findings on decline in physician participation in clinical research

Comprehensive source for treatment information of atrial fibrillation in the European market

Help Conquer Cancer Project taps World Community Grid to discover structure of cancer-related proteins

NOAA, FDA take additional steps to prevent tainted seafood from reaching U.S. market

China Pharmaceuticals first-quarter total revenue rises 50% to $7.05M

Sulindac shuts down cancer cell growth, initiates cell death: Study

Pediatric oncologist describes current state of science in combating neuroblastoma

Celator presents new data on CPX-351 liposome injection at European Hematology Association congress

FDA grants Fast Track status for Genzyme's alemtuzumab development program for MS

Behind the Numbers report: Employers' medical costs to increase by 9% in 2011

New path involving "innocent spectators" to defeat systemic sclerosis

Drug Discovery - Second Edition eBook

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News